Subcutaneous Immune Globulins (Cutaquig, Cuvitru, Hizentra, HyQvia, Xembify, Gammagard Liquid, Gammaked, Gamunex-C)

Covers SCIG products listed (Cutaquig, Cuvitru, Hizentra, HyQvia, Xembify, Gammagard Liquid, Gammaked, Gamunex‑C) only for FDA‑approved indications—primary humoral immunodeficiencies (e.g., CVID, X‑linked/congenital agammaglobulinemia, SCID, Wiskott‑Aldrich, IgG subclass deficiency, SAD, etc.) and maintenance therapy for CIDP—and excludes non‑listed/off‑label uses. Key requirements: prescriber/consult by an appropriate specialist (PID: allergist/immunologist/ENT/pulmonologist/infectious disease; CIDP: neurologist), diagnostic/lab documentation (age‑adjusted low IgG plus impaired antibody response or recurrent infections for PID; electrodiagnostic confirmation for CIDP), prior IVIG/SCIG dosing when switching, evidence of continued benefit for reauthorization, and approvals are issued for 12 months.

"Other agammaglobulinemia due to absence of B-cells"

Sign up to see full coverage criteria, indications, and limitations.